Crinetics Pharmaceuticals Inc
Atvērts
SektorsVeselības aprūpe
84.95 0.13
Pārskats
Akcijas cenas izmaiņa
24h
Min
84.95
Max
84.95
Ienākumi | 7M -121M |
|---|---|
Pārdošana | 14M 25M |
EPS | -1.14 |
Peļņas marža | -481.149 |
Darbinieki | 594 |
EBITDA | -4.7M -131M |
Rekomendācijas | Neitrāls |
|---|---|
Prognoze 12 mēnešiem | +0.72% upside |
Tirgus kapitalizācija | 148M 9B |
|---|---|
Iepriekšējā atvēršanas cena | 84.82 |
Iepriekšējā slēgšanas cena | 84.95 |
Crinetics Pharmaceuticals Inc Grafiks
Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.
Saistītās ziņas
Salīdzinājums
Cenas izmaiņa
Crinetics Pharmaceuticals Inc Prognoze
Cenas mērķis
By TipRanks
0.72% augšup
Prognoze 12 mēnešiem
Vidējais 85.56 USD 0.72%
Augstākais 95 USD
Zemākais 80 USD
Pamatojoties uz 11 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Crinetics Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.
Finanšu rādītāji
$
Par Crinetics Pharmaceuticals Inc
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.